Nursing homes have borne the brunt of the COVID-19 pandemic, but recently released data show that the severity of outbreaks in these facilities has varied substantially across the United States. Some have argued that policy decisions have driven the variation in outcomes observed in nursing homes, while a competing theory is that nursing home outbreaks largely mirror the surrounding area.
Last October, a new controversy erupted over the progressivity of the American tax system. The brouhaha was prompted by a new book, The Triumph of Injustice, by economists Emmanuel Saez and Gabriel Zucman. In it, the authors claim that the highest-earning Americans’ tax rate has fallen below everyone else’s.
A large share of total COVID-19 deaths in the United States have occurred in nursing homes, prompting the Centers for Medicare & Medicaid Services (CMS) to begin reporting facility-level data on COVID-19 rates at nursing homes.
“The result of those changes is a 4 percent dip in total charitable giving, and, ‘for middle- to upper-middle-income tax filers, the doubling of the standard deduction is responsible for nearly all the change in giving,’ Alex Brill and Derrick Choe, both of the American Enterprise Institute, explained in a 2018 analysis.”
The first widely reported COVID-19 deaths in the United States were nursing home patients in Washington State on February 28. Numerous accounts of similar outbreaks soon followed, including 47 deaths at a nursing home in Minnesota (as of April 30), 54 deaths at a nursing home in Massachusetts (as of May 4), and 81 deaths at a facility in New Jersey (as of May 27).
“The establishment of a shared savings model has the potential to increase health care savings, biologic competition, and biosimilar utilization if implemented in Medicare Part B, according to Alex Brill, founder of Matrix Global Advisors (MGA) and a resident fellow at the American Enterprise Institute (AEI), who makes the case in a new research paper.”
As the United States marks the tenth anniversary of the establishment of a biosimilars pathway, many experts express frustration that the US lags behind
Europe. A new white paper from Matrix Global Advisors carefully examines the US and European biosimilars markets and finds that the comparison between the markets is nuanced.
“…net employment at ESOPs climbed over 60% during 2001-2011 vs. no change elsewhere, concludes research by Alex Brill, CEO of consulting firm Matrix Global Advisors.”
Matrix Global Advisors (MGA) today released a new report, “Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition,” by MGA founder and CEO Alex Brill. The report identifies a unique opportunity in Medicare Part B to boost biosimilar utilization through the establishment of a shared savings demonstration model administered by the Centers for Medicare & Medicaid Services Innovation Center.
“We want the program to work and I think that sadly what we’re seeing is that the program is working quite well. And I say sadly because we are seeing tens of millions of people process through that system and we’re going to continue to see that I think for the next few weeks as the backlogs in certain states get worked through…”
“‘That could help accelerate the rebound if we can just kind of mothball the economy and then turn back on the same economy with the same manager-employee relationship,” said Alex Brill, a resident fellow at the right-leaning American Enterprise Institute.”
Alex Brill was one of the panelists discussing his “commitment to expand biosimilar use in the United States and how physicians and government officials are looking to help.
Recent news about e-cigarette misuse has fueled both public misperception and policy responses that are likely to have unintended consequences. As the US vaping market continues to evolve, policymakers face the tricky challenge of safeguarding the potential for positive public health outcomes from e-cigarettes, which offer a lower-risk alternative to traditional cigarettes, while ensuring reasonable protections against youth use.
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.
In anticipation of the December jobs report number being released later in the morning, Brill joins the morning news program to discuss his predictions that the number “will be right on the quarterly trend.”
Have a Question?
Get In Touch
Get Our latest news
1350 Connecticut Avenue NW
Washington, DC 20036